Medical Properties Trust reported a Q2 2024 net loss of $320.6 million ($0.54 per share), compared to a net loss of $42.0 million ($0.07 per share) in Q2 2023. The wider loss was primarily driven by $410 million impairment of real estate in its Massachusetts partnership with Macquarie and a $160 million unfavorable fair value adjustment to its PHP Holdings investment. Total revenues declined 21% to $266.6 million.The company completed several major transactions, including the Utah Transaction generating $1.1 billion in proceeds and the sale of five Prime properties for $250 million plus a $100 million mortgage loan. These asset sales resulted in approximately $385 million in gains. Additionally, MPT closed an £631 million secured loan facility with a 6.877% fixed rate backed by 27 UK properties leased to Circle affiliates.On August 6, 2024, MPT amended its credit facility...Show More

Medical Properties Trust reported a Q2 2024 net loss of $320.6 million ($0.54 per share), compared to a net loss of $42.0 million ($0.07 per share) in Q2 2023. The wider loss was primarily driven by $410 million impairment of real estate in its Massachusetts partnership with Macquarie and a $160 million unfavorable fair value adjustment to its PHP Holdings investment. Total revenues declined 21% to $266.6 million.The company completed several major transactions, including the Utah Transaction generating $1.1 billion in proceeds and the sale of five Prime properties for $250 million plus a $100 million mortgage loan. These asset sales resulted in approximately $385 million in gains. Additionally, MPT closed an £631 million secured loan facility with a 6.877% fixed rate backed by 27 UK properties leased to Circle affiliates.On August 6, 2024, MPT amended its credit facility, reducing the maximum borrowing to $1.28 billion and modifying certain covenants through September 2025. The company maintains $1.2 billion in liquidity and expects to meet its debt obligations through asset sales, rent collections and capital market activities, though faces challenges with Steward's bankruptcy process and limitations on accessing certain public market funding options until June 2025.